NCT02529930 2022-07-13
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
Nykode Therapeutics ASA
Phase 1/2 Completed
Nykode Therapeutics ASA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins